Drug – bio-affecting and body treating compositions – Foam
Reexamination Certificate
2004-12-12
2011-10-04
Haghighatian, Mina (Department: 1616)
Drug, bio-affecting and body treating compositions
Foam
C514S956000, C424S045000, C424S437000, C424S400000
Reexamination Certificate
active
08030362
ABSTRACT:
The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.
REFERENCES:
patent: 4241048 (1980-12-01), Durbak
patent: 4305936 (1981-12-01), Klein
patent: 4915934 (1990-04-01), Tomlinson
patent: 5322683 (1994-06-01), Mackles
patent: 5369131 (1994-11-01), Poli et al.
patent: 5393528 (1995-02-01), Staab
patent: 5397564 (1995-03-01), Seki et al.
patent: 5401741 (1995-03-01), Sato et al.
patent: 5502076 (1996-03-01), Dixit et al.
patent: 5529782 (1996-06-01), Staab
patent: 5635469 (1997-06-01), Fowler et al.
patent: 5679665 (1997-10-01), Bergamini et al.
patent: 5697532 (1997-12-01), Wilder et al.
patent: 5744166 (1998-04-01), Illum
patent: 5759520 (1998-06-01), Sachetto
patent: 5843930 (1998-12-01), Purwar et al.
patent: 5965549 (1999-10-01), Purwar et al.
patent: 6030931 (2000-02-01), Vinski et al.
patent: 6032836 (2000-03-01), Hiscocks et al.
patent: 6126920 (2000-10-01), Jones et al.
patent: 6238650 (2001-05-01), Lapidot et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6521213 (2003-02-01), Mautone
patent: 6534087 (2003-03-01), Busson et al.
patent: 6612468 (2003-09-01), Pritchett et al.
patent: 6660282 (2003-12-01), Crotty et al.
patent: 6702155 (2004-03-01), Rebne
patent: 6730288 (2004-05-01), Abram
patent: 6764470 (2004-07-01), Dimick
patent: 2002/0064541 (2002-05-01), Lapidot et al.
patent: 2003/0178022 (2003-09-01), Davies et al.
patent: 2004/0057922 (2004-03-01), Schmid et al.
patent: 2005/0031547 (2005-02-01), Tamarkin et al.
patent: 0933486 (1963-08-01), None
patent: WO 2004/037225 (2004-05-01), None
Cortifoam®, Drug information by Drug.com, Obtained online on Nov. 9, 2010.
Cortifoam®, PDR 1995 Edition, pp. 1949-1950.
Hannley, M.T. et al., “Use of ototopical antibiotics in treating 3 common ear diseases”, Otolaryngol Head Neck Surg, (2000), vol. 116, pp. 924-940.
U.S. Appl. No. 60/492,385, filed Aug. 4, 2003, from prosecution history of U.S. Appl. No. 10/835,505, published as US2005/0031547.
U.S. Appl. No. 60/530,015, filed Dec. 16, 2003, from prosecution history of U.S. Appl. No. 10/835,505, published as US2005/0031547.
Marom et al., “Comparison of safety and efficacy of foam-based versus solution-based ciprofloxacin for acute otitis externa,” Otolaryngology—Head and Neck Surgery, 143:492-499 (2010).
Ardizzone et al., “Mesalozine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs. Salofalc enema. The SAF-3 study group” Ital. J. Gastroenterol Hepatol 31:677-84 (1999) (Abstract).
Borelli et al., Creme or foam in pedal skin care: towards the ideal vehicle for urea used against dry skin, Int. J. Cosmet Sci 33:37-43 (2011).
Cortot et al., “Mesalamine foam enema vs. mesalamine liquid enema in active left-sided ulcerative colitis” Am J. Gastroenterpol 103(12):3106-14 (2008).
Farup et al., “Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regiments.” Scand J. Gastroenterol 30(2):164-170 (1995).
Franz “Bioavailability of clobetasol propionate in different vehicles.” Skin Pharmacol Appl Skin Physiol, 16(4):212-216 (2003) (Abstract).
Gross et al., “Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis” Aliment Pharmacol Ther 23:303-312 (2006).
Lucidarme et al., “Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis” Aliment Pharmacol Ther 11(2):335-340 (1997) (Abstract).
Ngo et al., “[5-aminosalycilic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicentered trial]”. Gastroenterol Clin Biol 16(6-7):558-563 (1992) (Abstract).
Ruddell et al., “Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocordisone enemas and rectal hydrocortisone foam” Gut, 21:885-889 (1980).
Somerville et al., “Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas” British Medical Journal 291:866 (1985).
Tarpila et al., “Budesinide Enema in active hemorrhagic proctitis—a controlled trial against hydrocortisone foam enema” Aliment Pharmacol. Ther 8(6):591-595 (1994) (Abstract).
Woodford et al., “Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam” J. Pharm Sci 66(1):99-103 (1977) (Abstract).
Browdy and Neimark PLLC
Haghighatian Mina
Otic Pharma Ltd.
LandOfFree
Compositions for treatment of ear disorders and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment of ear disorders and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment of ear disorders and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278669